Impact of human adipose tissue-derived stem cells on dermatofibrosarcoma protuberans cells in an indirect co-culture: An in vitro study

Zhaoqi YUAN
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital
https://orcid.org/0000-0003-2593-2229

Zhu ZHU
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Fangxing ZHU
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Feixue DING
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Yinmin WANG
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Xiuxia WANG
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Xusong LUO
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Jun YANG
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Fei LIU
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Di SUN (✉ sundi1980hn@sina.com)
Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

Research

Keywords: Dermatofibrosarcoma Protuberans (DFSP), Adipose Tissue Derived Stem Cells (ADSCs), Crosstalk, Skin Therapy, Regenerative medicine

DOI: https://doi.org/10.21203/rs.3.rs-476577/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

This is the first study to evaluate the crosstalk between human adipose tissue-derived stem cells (ADSCs) and dermatofibrosarcoma protuberans (DFSP) cells with regard to the potential of using ADSCs in cell-based skin regenerative therapies. The aim was to identify the potential oncological risks of placing ADSCs in proximity of the tumor microenvironment of DFSP cells.

Methods

Primary DFSP cells were indirectly co-cultured with ADSCs in a conditioned medium or in a Transwell system. Crosstalk was analyzed by assessing proliferation, migration, invasion, angiogenesis, and tumor-associated genes and proteins. The results of these assays were compared between co-culture and mono-culture conditions.

Results

The proliferation, migration, invasion, and angiogenesis of DFSP cells in co-culture conditions significantly increased compared with those in mono-culture conditions; this was accompanied by an increase in the expression levels of beta-type platelet-derived growth factor receptor, collagen type I alpha 1 chain, vascular endothelial growth factor, hepatocyte growth factor, and basic fibroblast growth factor.

Conclusions

The current report clearly demonstrates that crosstalk between DFSP cells and ADSCs can enhance the malignant properties of DFSP cells in vitro, which should not be neglected when considering the clinical use of isolated human ADSCs in skin regenerative therapies.

Background

Human mesenchymal stem/stromal cells (hMSCs) are a heterogeneous ensemble of cells with fibroblast-like morphology and can proliferate and form colonies in vitro. Additionally, hMSCs are capable of undergoing multilineage differentiation. Owing to the beneficial immunomodulatory and regenerative properties of hMSCs, these cells have received much attention as potential agents for therapies [1]. Adipose tissue-derived stem cells (ADSCs), an abundant and readily available subset of hMSCs, can be largely extracted from subcutaneous human adipose tissue; thus, they are the most suitable cell source for stem cell-based therapies [2]. ADSCs have tremendous plasticity with tri-lineage differentiation potential; these cells can differentiate into osteocytes, chondrocytes, and adipocytes [3]. ADSCs can affect cells in their microenvironment through the paracrine secretion of proteins [4]. Owing to their self-
renewal, unlimited proliferative, proangiogenic, and immunomodulatory properties, ADSCs have been used as attractive adjuncts in the form of cell-assisted lipotransfer to improve wound healing, angiogenesis, tissue engineering, and soft tissue augmentation after reconstructive surgery [5]. Recently, it has been reported that ADSCs loaded with biomaterials as antitumor drug carriers selectively target solid tumors during thermo/chemotherapy. This can improve the typical drug delivery methods, correlating with magnetic resonance imaging tracking for diagnostic applications [6, 7].

Interestingly, ADSCs have also been shown to exhibit duality. These cells not only greatly promote cell regeneration but also facilitate the progression of tumors [1, 8]. ADSCs have been reported to be actively recruited into the tumor nidus and surrounding inflammatory microenvironment by cancer cells, thus increasing tumor vascularity [9]. Moreover, ADSCs have been suggested to differentiate into cancer-associated fibroblasts (CAFs), which form an essential part of the tumor stroma [10]. Therefore, they serve as an important promoter of tumor growth, invasion, and metastasis through secretion of various cytokines and proteases [11, 12]. Additionally, ADSCs are similar to CAFs in their cancer-promoting properties; therefore, ADSCs interact within the tumor microenvironment (TME), promoting cancer cell proliferation, viability, invasiveness, and chemoresistance [3]. Consequently, there have been concerns about the oncological safety of using ADSCs in cell-based regenerative therapy for reconstruction after cancer surgery [8]. Although research focusing on ADSCs and tumors has been gaining attention, the impact of ADSCs on dermatofibrosarcoma protuberans (DFSP) has not been reported.

DFSP is a rare, low-grade, soft tissue sarcoma; it is the second most common type of cutaneous soft tissue sarcoma [13]. Problems such as initial misdiagnoses, prolonged time to accurate diagnosis, and large tumor size at the time of diagnosis are common because of the lack of specific DFSP characteristics [14]. In addition, with highly irregular shapes [15], these tumor cells often infiltrate the dermis and spread into the underlying subcutaneous tissue, which results in incomplete removal and high recurrence rate of DFSP [16]. Hence, to achieve clear surgical margins, extended excision is necessary, which causes large defects in the skin and soft tissue. It is challenging for plastic and reconstructive surgeons to repair these defects. Some studies have mentioned fat grafting after sarcoma surgery but cautioned against its oncological safety [17]. Although they found no evidence of hazardous factors after extra fat grafting in patients with sarcoma, their findings highlight the need for further studies on the interaction between the fat microenvironment, adipose-derived stem cell-related growth factors, and sarcomas [17]. Therefore, it is important to evaluate the oncological risk of possible interactions between co-localized ADSCs and DFSP cells to understand whether ADSCs can be used as drug carriers in cell-based therapy or as targets for neoadjuvant treatment of DFSP.

In this study, we co-cultured primary DFSP cells with ADSCs. We quantified the changes in proliferation, migration, invasion, and angiogenesis, and compared the results with those of DFSP cell mono-cultures. In addition, we attempted to gain further insight into the interactions from the perspective of genes and proteins.

**Methods**
ADSC isolation, cultivation, and identification

Human adipose tissue samples were obtained by liposuction of the abdominal wall from three different donors. After rinsing three times with phosphate-buffered saline (PBS), the samples were digested with 0.1\% (w/v) collagenase IV (NB4; Serva, Heidelberg, Germany) for 2 h. Cells were concentrated by centrifugation at 1500 rpm at 37°C for 5 min to obtain ADSCs. ADSCs were cultured in low-glucose Dulbecco’s modified Eagle’s medium (DMEM; HyClone, Logan, UT, USA) supplemented with 10\% fetal bovine serum (FBS; ScienCell Research Laboratories, Inc., San Diego, CA, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in 5\% CO₂ until they reached 80–90\% confluence; thereafter, they were dissociated with 0.05\% trypsin-EDTA and passaged. The cells of passages 2–6 were combined and used for further characterization and in vitro differentiation.

ADSC identification

Osteogenic Differentiation Assay Human ADSCs (2×10^4 cells/cm^2) were seeded in 6-well plates that were pre-coated with a 0.1\% gelatin solution and then cultured in DMEM containing 10\% FBS, 1\% antibiotic/antimycotic, 0.01 µM 1,25-dihydroxyvitamin D3, 50 µM ascorbate-2-phosphate, and 10 mM β-glycerophosphate (HUXMD-90021, Cyagen Bioscience, Inc., Santa Clara, CA, USA). The medium was changed every three days. After 28 days of culture at 37°C under 5\% CO₂, the cells were washed twice with PBS, fixed in 4\% paraformaldehyde for 30 min, and stained with 0.3\% Alizarin red for 5 min. After two washes with PBS, the cells were observed and photographed under a phase contrast inverted microscope (Olympus, Tokyo, Japan).

Chondrogenic Differentiation Assay Human ADSCs (4×10^5 cells) were seeded in 15 mL centrifuge tubes filled with DMEM containing 10\% FBS, 1\% antibiotic/antimycotic, 6.25 µg/mL insulin, 10 ng/mL TGFβ1, and 50 nM ascorbate-2-phosphate (HUXMD-90041, Cyagen Bioscience, Inc.). The medium was changed every three days. After 28 days of culture at 37°C under 5\% CO₂, the cartilage balls were formalin-fixed, paraffin-embedded, sectioned, and stained with Alcian blue. The sections were observed and photographed under a light microscope (Leica Microsystems GmbH, Wetzlar, Germany).

Adipogenic differentiation assays Human ADSCs (2×10^4 cells/cm^2) were seeded in 6-well plates in DMEM containing 10\% FBS, 1\% antibiotic/antimycotic solution, 0.5 mM isobutyl-methylxanthine, 1 µM dexamethasone, 10 µM insulin, and 200 µM indomethacin (Cyagen Bioscience, Inc., Inc., HUXMD-90031). The medium was changed every three days. After 28 days of culture at 37°C under 5\% CO₂, the cells were washed twice with PBS, fixed in 4\% paraformaldehyde for 30 min, and stained with 0.3\% oil red O solution for 30 min. After two washes with PBS, the cells were observed and photographed under a phase contrast inverted microscope (Olympus).

Flow cytometric assay
Flow cytometric analysis was used to identify the markers of ADSCs according to a published paper. Briefly, hADSCs were harvested and washed thrice with PBS. The cell suspension was incubated with fluorescein isothiocyanate-conjugated antibodies against CD29, CD31, CD45, and CD90 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and phycoerythrin-conjugated antibodies against CD105 and CD44 (Santa Cruz Biotechnology, Inc.) at 37°C for 30 min in the dark, washed, and resuspended in PBS and subjected to flow cytometry (BD Biosciences, San Jose, CA, USA).

**DFSP cell isolation and cultivation**

Three DFSP samples from one man and two women were obtained after excision from the corresponding sites (Table 1). Samples were soaked in chloromycetin for 30 min, cut into as small pieces as possible, and then digested with 0.1% collagenase IV for 30 min at 37°C. After centrifugation, cells were suspended in high-glucose DMEM (Hyclone, Logan, UT, USA) with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C in 5% CO₂. Cells at passages 2–6 were used in this experiment.

| Sample | Sex    | Age | Location       |
|--------|--------|-----|----------------|
| 1      | Female | 33  | Anterior chest |
| 2      | Male   | 42  | abdomen        |
| 3      | Female | 46  | left clavicle  |

**DFSP-ADSC-co-cultures**

**Indirect co-culture by conditioned medium**

Human ADSC conditioned medium. To prepare conditioned medium (CM), 2×10⁵ ADSCs were seeded onto a six-well cell culture plate with DMEM/F12 (Hyclone, Logan, UT, USA) medium containing 10% FBS overnight, and the culture medium was replaced with DMEM/F12 serum-free (SF) and conditioned for 24 h. ADSC-CM was harvested, filtered through 0.22 µm filters (Jet Bio-Filtration, Guangzhou, China), and stored at -80°C until use.

**Indirect co-culture by Transwell system**

Co-culture of DFSP cells and ADSCs was performed using a Transwell system. First, 2×10⁵ ADSCs were seeded onto a polyester membrane Transwell-clear insert (pore size 0.4 µm, Corning Incorporated, Corning, NY, USA). Next, DFSP cells were seeded onto the bottom of a six-well cell culture plate with the same cell density in DMEM/F12 medium containing 10% FBS overnight, and then the medium was replaced with fresh DMEM/F12 SF to eliminate non-adherent cells. At the required time point, DFSP cells or supernatants (Co-cultured DFSP/ADSC-CM) were collected and stored at -80°C until use. Isolated DFSP cells seeded on six-well culture plates served as controls and were treated as the co-cultured cells were.
Proliferation assays

The ability of ADSC-CM to induce DFSP cell proliferation was assessed using a Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s protocols. Briefly, DFSP cells (2×10^3/well) were seeded in 96-well plates. After 24 h, the DFSP cells were treated with ADSC-CM (supplemented with 1% FBS) and DMEM/F12 (supplemented with 1% FBS) as a control. The medium was replaced every 48 h. After 1, 3, 5, and 7 days, the cells were washed three times with PBS, and 100 µL of fresh culture medium with 10 µL of CCK-8 reagent was added to each well and incubated at 37°C for 2 h. The absorbance of each sample, which was proportional to the number of viable cells, was measured at a wavelength of 450 nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). Each group was prepared in triplicates. The experiment was repeated three times.

Cell migration assays

Scratch wound healing

DFSP cells (2×10^5/well) were seeded in 6-well culture plates and grown in complete medium until they reached 80% confluence. Then, monolayers were scratched using a 200 µL sterile plastic pipette tip (PipetTipFinder, LLC, Knoxville, TN, USA), which was placed perpendicular to the bottom of the dish as previously described and then washed three times with PBS. DFSP cells were then treated with ADSC-CM SF for 24 h. Positive controls were set up with DMEM/F12 + 10% FBS and negative controls with DMEM/F12 SF. Scratch wound closure was monitored using a phase contrast inverted microscope (Olympus) at 0, 6, 12, and 24 h. It was then employed to measure the area between the opposite edges of the wound, which was semi-quantified with Image J software 1.46r (National Institutes of Health, USA). The migration rate was calculated using the following formula: Migration rate (%) = (Gap0h-Gap24h)/Gap0h×100%. In each sample, five views were randomly photographed to obtain the mean, and the final mean rate plus standard deviation (mean ± SD) was derived from the means of three cell samples.

Transwell assay

Cell migration was also evaluated using a 24-well Transwell chamber (Corning, pore size 8.0 µm). For this purpose, once 80% confluence was achieved, DFSP cells were collected and seeded in the upper chamber of an 8.0 µm pore size insert (2×104 cells/well) with DMEM/F12 SF and allowed to migrate toward DMEM/F12 + 10% FBS (positive control), DMEM/F12 SF (negative control), or ADSCs (2×104 cells/well; experimental) present in the lower chamber. After incubation for 12 and 24 h, the non-migrating cells in the upper chamber were removed with a cotton swab, and the remaining cells were fixed in methanol for 30 min. Cells that migrated to the lower surface of the membrane were stained with 0.5% crystal violet, diluted for 5 min, gently washed three times in PBS, air-dried, and observed and photographed with a microscope (Olympus). Five fields were randomly chosen for each assay. Quantification was performed by processing all obtained images using Image J software 1.46r (National Institutes of Health). The
average number of migrating cells in five random fields was taken as the cell migration number of the group. All experiments were repeated three times.

**Cell invasion assay**

The capacity of ADSC-CM to induce DFSP cell invasion was tested using a 24-well Transwell chamber (8 µm pore size insert) pre-coated with Matrigel matrix (Cat. No. 356234, Corning Incorporated) according to the manufacturer's instructions. Briefly, 100 µL of the diluted Matrigel matrix (800 µg/mL in SF medium) was carefully added to the center of each Transwell insert for invasion assays. The plate was incubated at 37°C for 1 h to allow the Matrigel to form a gel. The DFSP cells were counted and diluted to a density of \(2 \times 10^5\) cells/mL with DMEM/F12 + 10% FBS (positive control), DMEM/F12 SF (negative control), and ADSC-CM (experimental). Next, 100 µL of the cell suspension was seeded into the upper chamber of each Transwell. Thereafter, 800 µL of culture medium with 5% FBS was added to the lower chambers. The cells were cultured in a humidified incubator at 37°C with 5% CO\(_2\) for 36 h. The cells inside the Transwell inserts were gently removed using cotton swabs, and the cells on the lower surface of the membrane were stained with crystal violet for 5 min. The Transwell inserts were washed three times with PBS to remove unbound crystal violet and then air-dried. The invaded cells were observed and photographed under a microscope (Olympus). Five fields were randomly chosen for each assay. Quantification was performed by processing all obtained images using Image J software 1.46r (National Institutes of Health). The average number of migrating cells in these five fields was taken as the cell invasion number of the group. All experiments were repeated three times.

**Angiogenic properties assay**

To evaluate the effect of proteins secreted by isolated DFSP cells or ADSCs or both co-cultured cells on angiogenesis, SF CM of each condition was collected at 24 h of cell culture (processing with the abovementioned method). Human umbilical vein endothelial cells (HUVECs) were obtained from the Cell Bank of the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Wells of a 96-well plate were coated with Matrigel matrix, and 1×10^4 HUVECs were seeded onto the matrix in each well. The ADSC-CM, DFSP-CM, and co-cultured DFSP/ADSC-CM were added and incubated for 4 h. Tube formation was visualized using bright-field microscopy. Quantification was performed by processing all obtained images using Image J software 1.46r (National Institutes of Health). The experiments were independently reproduced at least three times.

**Quantitative real-time polymerase chain reaction**

After 24 h of co-culture (processing with the above method *Indirect co-culture by Transwell system*), total RNA was extracted using EZ-press RNA Purification Kit (B0004D, EZBioscience, Roseville, USA) according to the manufacturer's instructions. RNA purity was evaluated by calculating the A260/A280 ratio, which should be between values of 1.8 and 2.0. The mRNA was reverse transcribed into cDNA with 4×Reverse Transcription Master Mix (A0010, EZBioscience), and then real-time quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the cDNA as a template and 2×SYBR Green qPCR Master Mix (A0001, EZBioscience) according to the manufacturer’s instructions. Primers were synthesized by
Sangon Biotech Co. (Shanghai, China). Target gene expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase and quantified using the comparative Ct method. The mean minimal cycle threshold value was calculated from triplicate reactions. The primers used for qRT-PCR analysis are listed in Table 2.

| Gene      | Forward primer (5’–3’)          | Reverse primer (5’–3’)          |
|-----------|---------------------------------|---------------------------------|
| GAPDH     | GGGAGCTTTGCTCATCAATGGAA         | AGAGATGATGACCTTTTTGGCTC         |
| PDGFRB    | AGCACCTTCGTTCTGACCTG            | TATTCTCCCGTGCTAGCCCCA           |
| COL1A1    | GAGGGCCAAGACGAAGACATC           | CAGATCACGTCATCGCAACAC           |
| VEGF      | AGGCCAGATCATCATACGAAGT          | AGGGTCTCGATTGGATGGCA            |
| HGF       | GCTATCGGGGTTAAGACCTACA          | CGTAGGCCTACCTCTGGATTGC          |
| bFGF      | AGAAGAGCGACCCTCACATCA           | CGGTTAGCACACACACCTCTTTC         |

### Western blotting analysis

After 48 h of co-culture (processing with the above method 3.2), total protein was extracted from the DFSP cells with RIPA lysis buffer as described previously [20]. Supernatants were collected, and their total protein concentration was determined using the BCA Protein Assay Kit (Cat. No. P0010, Beyotime, Shanghai, China). Protein samples were completely denatured by boiling in bromophenol blue sample buffer for 5 min, separated by electrophoresis on 7.5% sodium dodecyl sulphate-polyacrylamide gel, and then transferred onto polyvinylidene difluoride (PVDF) membranes. Non-specific antibody binding was blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20 for 1 h at room temperature. The primary antibodies used were as follows: beta-type platelet-derived growth factor receptor (PDGFRB) (1:5000, Cat. No. ab32570, Abcam, Cambridge, MA, USA) and COL1A1 (1:1000, Cat. No. ab34710, Abcam). Immunoblotting was performed using specific primary antibodies and secondary antibodies conjugated to horseradish peroxidase. Protein blots were developed using an enhanced chemiluminescence method. β-actin (1:2000, Cat. No. ab8226, Abcam) was used as a loading control, and the results were analyzed as the detected β-actin ratio.

### Enzyme-linked immunosorbent assay

After 48 h of culturing, supernatants were collected from the DFSP-mono-culture and DFSP-ADSC-co-culture in Transwell (processing with the above method 3.2) and stored at -80°C until use. The levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and basic fibroblast growth factor (bFGF) were measured using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer’s protocol. Standard curves were generated to calculate the cytokine levels. The experiments were independently repeated thrice.
Statistical analysis

All quantitative results are presented as mean ± standard deviation (SD). Statistical comparisons were performed using a Student's t-test in three independent experiments. GraphPad Prism version 7.0 software (GraphPad Inc., La Jolla, CA, USA) was used for data analysis. Statistical significance was set at p < 0.05.

Results

ADSCs displayed multipotent differentiation and expressed stem cell markers

The multipotency of ADSCs was examined by osteogenic, chondrogenic, and adipogenic differentiation assays. ADSCs were cultured and induced with osteogenic medium for four weeks and stained with Alizarin red to confirm the presence of calcium deposits (Fig. 1A). ADSCs were induced with chondrogenic medium for four weeks, and sections of cartilage balls were stained with Alcian blue (Fig. 1B). ADSCs were induced with adipogenic medium for four weeks and developed an adipogenic phenotype, which showed the presence of lipid droplets in the cells by oil red O staining (Fig. 1C). The ADSCs were characterized using mesenchymal stem cell surface markers as CD29+ (87.37%), CD31+ (0.5%), CD45+ (2.18%), CD90+ (95.62 %), CD105+ (96.32%), and CD44+ (98.98%) (Fig. 1D-I) [21]. These results revealed that the ADSCs isolated from human adipose tissue demonstrated typical ADSC characteristics.

ADSC-CM promoted DFSP cell proliferation

The CCK-8 assay was used to evaluate the effect of ADSC-CM on DFSP cell proliferation. As shown in Fig. 3, ADSC-CM promoted significant DFSP cell proliferation at days 5 and 7 compared with that in control condition (p < 0.05). There were no significant differences in cell proliferation rates between the experimental and control conditions during the first three days.

ADSC-CM or ADSCs promoted DFSP cell migration

We evaluated the ability of ADSCs to affect DFSP cell migration. First, as shown in Fig. 4A, the ability of ADSC-CM to affect DFSP cell migration was tested using a scratch wound model in which DFSP cells were treated with ADSC-CM (experimental), DMEM/F12 + 10% FBS (positive control), or DMEM/F12 SF (negative control). At 6 h, DFSP cells of the negative control (DMEM/F12 SF) group migrated to 9.3 ± 1.5% of the scratched area, whereas the ADSC-CM-treated DFSP cells migrated to 15.9 ± 2.3% of the area (p < 0.05, Fig. 4B). At 12 h, the DFSP cells of the negative control group had migrated to 8.7 ± 0.1% of the scratched area, whereas the ADSC-CM-treated DFSP cells migrated 17.5 ± 4.7% of the area (p < 0.05, Fig. 4C). At 24 h, the DFSP cells from the negative control group had migrated to 13.3 ± 2.8% of the scratched area, whereas the ADSC-CM-treated DFSP cells had migrated 47.4 ± 4.4% of the area (p < 0.05,
Fig. 4D). These results showed that treatment with ADSC-CM significantly promoted the migration of DFSP cells at 6, 12, and 24 h (1.71-, 2.01-, and 3.56-fold, respectively) compared with the negative control (DMEM/F12 SF).

Next, we tested if the presence of ADSCs in the basal compartment could induce a stronger response than that generated by ADSC-CM in a Transwell system (Fig. 5B). As shown in Fig. 5A, the effect of ADSCs on DFSP-migrated cell counts was tested using the Transwell system, in which DFSP cells were incubated with ADSCs (experimental), DMEM/F12 + 10% FBS (positive control), or DMEM/F12 SF (negative control). At 12 h, 4.7 ± 1.2 DFSP cells had migrated in the negative control group, whereas 52.5 ± 2.4 cells had migrated in the experimental group (p < 0.05, Fig. 5C). At 24 h, 6.2 ± 2.2 cells showed migration in the negative control group, whereas the number was 38.2 ± 12.6 cells in the experimental group (p < 0.05, Fig. 5D). The results showed that treatment with ADSCs more significantly promoted the migration of DFSP cells at 12 and 24 h time points (11.17- and 6.16-fold, respectively) compared with that seen in negative control conditions (DMEM/F12 SF).

**ADSC-CM enhanced DFSP cell invasion**

The invasive properties of DFSP cells allow them to digest the Matrigel matrix, a basement membrane preparation extracted from the Engelbreth-Holm-Swarm mouse sarcoma. As shown in Fig. 6A, the effect of ADSC-CM on DFSP-invaded cell counts was tested using a Transwell system with pre-coated Matrigel; DFSP cells were treated with DMEM/F12 + 10% FBS (positive control), DMEM/F12 SF (negative control), or ADSC-CM (experimental). At 36 h, 0.7 ± 0.8 cells in the negative control group had invaded the lower surface, whereas in the experimental group, 4.2 ± 1.9 cells showed invasion (p < 0.05, Fig. 6C). The results showed that treatment with ADSC-CM could promote the invasion of DFSP cells at 36 h (7-fold) more significantly than the negative control could (DMEM/F12 SF).

**Co-cultured DFSP/ADSC-CM enhanced angiogenic properties in vitro**

To evaluate the effect of proteins secreted by ADSCs, DFSP cells, and co-cultured DFSP cells and ADSCs on angiogenesis, HUVECs were incubated with different CMs (ADSC-CM, DFSP-CM, and co-cultured DFSP/ADSC-CM) that led to the formation of tubular networks. These were visible through inspection under an inverted light microscope after 4 h of incubation (Fig. 7A). We observed a significant increase in the number of meshes, total tube length, and total branch length of tubular networks formed by HUVECs cultured with co-cultured DFSP/ADSC-CM compared with those seen in the control groups (ADSC-CM or DFSP-CM; p < 0.05, Fig. 7B-D).

**ADSCs increased the expression of DFSP-related genes and the protein levels**
After DFSP cells were cultured with ADSCs using the Transwell system for 24 h, the mRNA levels of PDGFRB and collagen type I alpha 1 chain (COL1A1) in DFSP cells showed 1.4-fold and 1.5-fold increases, respectively, compared with the levels in mono-cultured DFSP cells (p < 0.05, Fig. 8A-B). After 48 h, in the co-cultured cells, the protein levels of PDGFRB were increased moderately and the protein levels of COL1A1 were increased significantly compared with those in the mono-cultured DFSP cells (Fig. 8C-E). Similar trends were observed in the qRT-PCR and Western blotting experiments.

**ADSCs increases growth factor gene expression in DFSP cells and growth factor secretion in the co-cultured DFSP microenvironment**

After DFSP cells were cultured with ADSCs using the Transwell system for 24 h, the mRNA expression of the pro-angiogenic genes VEGF, HGF, and bFGF in DFSP cells was elevated 1.32-fold, 1.2-fold, and 1.4-fold, respectively compared with those in the mono-cultured DFSP cells (p < 0.05, Fig. 9A-C). After 48 h, the levels of VEGF, HGF, and bFGF secretion in the collected supernatants from the co-culture (experimental group) were significantly increased compared with those in the supernatants of the mono-cultured DFSP cells (control group). The concentration of VEGF in the experimental group was 98.0 ± 3.5 pg/mL, whereas it was 64.2 ± 3.9 pg/mL in the control group (p < 0.0001, Fig. 9D). The concentration of HGF in the experimental group was 287.4 ± 14.1 pg/mL, whereas it was 202.5 ± 12.0 pg/mL in the control group (p < 0.01, Fig. 9E). The concentration of bFGF in the experimental group was 31.6 ± 6.3 pg/mL, whereas it was 19.6 ± 1.8 pg/mL in the control group (p < 0.05, Fig. 9F).

**Discussion**

Many studies have recognized that the interaction/crosstalk between tumors and their stroma plays an important role in tumor progression [22]. ADSCs are ubiquitously distributed in all adipose tissues and may interact directly with tumors [23]. Tumors have also been characterized as niduses of chronic inflammation or wounds that never heal, which could attract MSCs and a diverse complement of stromal cells from various origins [25]. This feature is also known as tumor-homing ability [25]. Therefore, it has been observed that in situ or recruited cells such as ADSCs contribute to the acquisition of hallmark traits, such as immunomodulation, angiogenesis, invasion and metastasis, and apoptotic resistance [26].

The is the first study to show the effects of human ADSCs on human DFSP cells by co-culture in vitro; we found that ADSCs promoted the proliferation, migration, invasion, and angiogenic properties of DFSP cells. Furthermore, in DFSP cells, changes in PDGFRB and COL1A1 gene expression and protein levels were observed. Additionally, a remarkable change in the secreted protein levels of VEGF, bFGF, and HGF in the co-cultured microenvironment was observed, which plays an important role in mediating the tumor-promoting effect. These changes strongly point towards serious adverse biological consequences that may arise in the in vivo co-presence of ADSCs and DFSP cells.

Our results clearly show an increased proliferation rate in DFSP cells after co-culture with ADSC-CM. These changes suggest that direct physical contact between ADSCs and DFSP cells is not required for ADSCs to regulate the proliferation of DFSP cells, and the major mechanism underlying this may be
related to their paracrine activity in the microenvironment. However, until now, there is no consensus in
the literature regarding the effect of ADSCs on tumor cell proliferation due to the differences in cell source
of cancer, model of cancer tested, or species studied [27].

Next, we observed that ADSC-CM and ADSCs could boost the migration of DFSP cells through indirect co-
culture. These results are consistent with previous reports on the increased migration of skin tumor cells,
such as malignant melanoma cells [28] and squamous cell carcinoma cells [12, 29], in response to
factors secreted by ADSCs. Even in the absence of the physical presence of ADSCs, the secretome of
ADSCs can promote DFSP cell migration. Interestingly, this effect was more prominent in the co-culture
Transwell system, where DFSP cells shared the same medium with ADSCs without direct physical
contact. This can be explained by the fact that the crosstalk between different cells together in the same
microenvironment could enhance action [30].

Increased migration, a key feature in the process of cellular invasiveness, is involved in the degradation of
the basement membrane and extracellular matrix [31]. The cell invasion assay demonstrated that ADSC-
CM could stimulate DFSP cells to degrade the matrix promptly and invade through the basement
membrane. In other words, the invasiveness of DFSP cells was increased. This is in line with the findings
of a previous study on the effect of MSCs on the metastatic ability of cancer cells, where MSCs were co-
injected with breast carcinoma cells, which caused a marked enhancement in distant metastasis. It is
worth stressing that this effect on invasive potential was only noticed when MSCs were injected close to
the engraft tumor [32].

To confirm the possible mechanisms by which ADSCs enhance the malignant biological behavior of
DFSP cells, the main features of DFSP in the co-cultured microenvironment were evaluated. The
expression of PDGFRB and COL1A1 in DFSP cells co-cultured with ADSCs was found to be elevated at
the mRNA and protein levels compared to those in controls, which was not surprising.

Soft tissue sarcomas have been suggested to contain PDGF autocrine loops. Co-expression of ligands
and receptors has been observed in clinical samples of fibroblast-derived tumors, such as DFSP [33].
DFSP presents with specific cytogenetic features, such as reciprocal translocations t(17;22) (q22;q13.1)
or supernumerary ring chromosomes derived from t(17;22) [34, 35]. The result of this rearrangement is
the upregulation of COL1A1-PDGFB fusion proteins that are processed to form mature PDGFB and then
activate PDGFB receptors (PDGFRB) [36] to form an autocrine loop, which contributes directly to DFSP
tumor development and growth [37]. PDGFB can also act on a variety of cells by stimulating mitogenicity
and chemotaxis [38]. Matrix metalloproteinases (MMPs) are extracellular matrix-degrading enzymes that
contribute to invasiveness. PDGFB can induce the production of MMP-1 and −2 in cultured fibroblasts
[39], which is demonstrated by the induction of MMP-9 by PDGFB in VSMCs. Thus, it can be hypothesized
that PDGF signaling contributes to invasion by MMP induction [40]. In addition, PDGFB can upregulate
the expression of its own receptor (PDGFRB) on capillary endothelial cells to stimulate angiogenesis [41]
through its ability to recruit pericytes and improve the development of vascular smooth muscle cells [42].
PDGFB also has important functions in reinforcing the structural integrity of vessels [43]; thus, it may
contribute to tumor angiogenesis through various mechanisms. It is important to note that PDGFB confers a tumorigenic phenotype to human tumor cells bearing PDGFBR but not to cells devoid of receptors [44]. Hence, the high expression of PDGFRB mRNA and protein in DFSP cells treated with ADSCs implies that ADSCs could reinforce the tumorigenicity of DFSP by regulating cell proliferation, survival, migration, and invasion, as well as deposition and turnover of the extracellular matrix [15, 45].

The processing of the chimeric COL1A1-PDGFB protein into PDGFB dimers also results in the production of significant quantities of the COL1A1 chains. These would be combined as trimers with COL1A2 chains and processed into mature collagen fibers in the extracellular medium [46]. Through collagen bundles, the neoplasm can invade laterally and deeply along connective tissue septae to proliferate [15]. In addition, recent studies have found that COL1A1 appears to exert an oncogenic effect, which promotes tumor migration by rearranging the actin cytoskeleton and regulating the planar polarity of the cells [47, 48]. COL1A1 is involved in forming the extracellular matrix of the tumor microenvironment. Some studies have also suggested that cellular COL1A1 expression could promote tumor metastasis, and increased COL1A1 levels were associated with poor survival [49]. Therefore, we considered that ADSCs could promote DFSP migration and invasion by increasing COL1A1 expression level in DFSP cells [15].

Finally, the co-cultured DFSP/ADSC-CM facilitated the formation of more tubular networks in HUVECs than did ADSC-CM or DFSP-CM alone. This means that the crosstalk between DFSP cells and ADSCs can regulate paracrine signaling in the TME to enhance angiogenesis, which is essential in the pathogenesis of rapid growth and metastasis in solid tumors.

Meanwhile, more proangiogenic factors like VEGF, HGF, and bFGF were detected in co-cultured DFSP/ADSC supernatant than in mono-cultured DFSP-supernatant. VEGF, also known as vascular permeability factor, is an endothelial cell-specific mitogen [51] that is probably the most potent pro-angiogenic factors described to date. VEGF is secreted by tumor cells or stromal cells, such as ADSCs [41]. By binding to its receptors on the endothelial cell surface, which promotes cell proliferation and migration, VEGF mediates vascular leakage and angiogenesis [52]. The growth of vessel sprouts is also guided by the VEGF gradient [53]. In addition, autocrine VEGF signaling contributes to the invasiveness of carcinomas by affecting the survival and migration of carcinoma cells [54]. bFGF is a heparin-binding mitogen that induces an angiogenic response by directly binding to tyrosine kinase receptors on endothelial cells [55]. VEGF and bFGF have a potent synergistic effect on the induction of angiogenesis in vitro [56]. HGF is a mitogen for hepatocytes and a fibroblast-derived factor that induces scattering in polarized epithelial cells [57]. It binds to the met-tyrosine kinase receptor and has been independently implicated in angiogenesis [58]. Furthermore, HGF has been shown to increase the expression of VEGF to initiate angiogenesis [59] and to act in synergy with VEGF to amplify angiogenesis [60, 61]. Therefore, we hypothesize that ADSCs increase the secretion of proangiogenic factors VEGF, HGF, and bFGF in the co-cultured DFSP microenvironment to stimulate angiogenesis.

Taken together, the in vitro co-culture of ADSCs and DFSP cells led to considerable changes in malignant behavior of the tumor cells. This points to a potentially increased oncological risk in vivo, which should
not be neglected when considering the clinical use of cell-assisted lipoaspirates in patients with DFSP or residual DFSP cells.

**Conclusion**

In the current study, we first explored the interactions between ADSCs and DFSP cells using an in vitro co-culture model to understand the effects of ADSCs on tumor development. This report provides evidence that ADSCs significantly affect multiple malignant features, such as gene expression, protein secretion, proliferation, migration, invasion, and angiogenesis, of DFSP cells in vitro. Therefore, ADSCs may strongly increase the risk of DFSP tumor development in vivo if administered near malignant tumor cells. Our results need to be considered when discussing the safety of ADSC-based therapies for patients with DFSP or residual DFSP cells. The informed consent forms for such procedures should mention the increased risk of cancer and relapse and the possibility of faster growth and dissemination of a pre-existing cancer [29]. Additionally, it seems crucial to rigorously screen all patients for residual lesions prior to the injection of adipose derivatives such as fat, stromal vascular fraction, or isolated ADSCs in adjacent tissues to avoid potential co-localization of ADSCs and DFSP cells.

**Abbreviations**

ADSCs, adipose tissue-derived stem cells

bFGF, basic fibroblast growth factor

CAFs, cancer-associated fibroblasts

CCK-8, Cell Counting Kit-8

CM, conditioned medium

COL1A1, collagen type I alpha 1 chain

DFSP, dermatofibrosarcoma protuberans

DMEM, Dulbecco’s modified Eagle’s medium

ELISA, enzyme-linked immunosorbent assay

FBS, fetal bovine serum

HGF, hepatocyte growth factor

hMSCs, human mesenchymal stem/stromal cells

HUVECs, Human umbilical vein endothelial cells
MMPs, matrix metalloproteinases

PBS, phosphate-buffered saline

PDGFRB, Beta-type platelet-derived growth factor receptor

PDGFRB, PDGFB receptors

qRT-PCR, real-time quantitative real-time polymerase chain reaction

SF, serum free

TME, tumor microenvironment

VEGF, vascular endothelial growth factor

**Declarations**

**Ethics approval and consent to participate**

All these experiments were approved by Shanghai Jiao Tong University of Medicine ethics committee and all patients consented to the respective use of their tissues. (Approval Number: HJYKLS[2018]239).

**Consent for publication**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article and its supplementary information files.

**Competing interests**

None.

**Funding**

This study was supported by grants of the National Natural Science Foundation of China (81871576; 81701901; 81801946) and Shanghai Municipal Key Clinical Specialty (shslczdk00901).

**Authors’ contributions**

YZQ and ZZ planned and performed the experiments and completed the manuscript. YZQ and ZFX revised the manuscript. DFX, WYM and WXX helped YZQ to perform experiments. YJ and LXS supervised the the study. YZQ, LF and SD designed the study. All authors discussed and approved the manuscript.
Acknowledgements

This study was financially supported by the National Natural Science Foundation of China and Shanghai Municipal Key Clinical Specialty. We like to thank our group members.

References

1. Ilmer Matthias, Vykoukal Jody, Recio Boiles Alejandro et al. Two sides of the same coin: stem cells in cancer and regenerative medicine. FASEB J. 2014; 28: 2748-61. doi:10.1096/fj.13-244640.

2. De Francesco Francesco, Ricci Giulia, D’Andrea Francesco et al. Human Adipose Stem Cells: From Bench to Bedside. Tissue Eng Part B Rev. 2015; 21: 572-84. doi: 10.1089/ten.TEB.2014.06.08.

3. Freese Kyle E, Kokai Lauren, Edwards Robert P et al. Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: a systematic review. Cancer Res. 2015; 75: 1161-8. doi: 10.1158/0008-5472.CAN-14-2744.

4. Kapur Sahil K, Katz Adam J. Review of the adipose derived stem cell secretome. Biochimie. 2013; 95: 2222-8. doi: 10.1016/j.biochi.2013.06.001.

5. Alperovich M, Lee Z H, Friedlander P L et al. Adipose stem cell therapy in cancer reconstruction: a critical review. Ann Plast Surg. 2014; 73. doi: 10.1097/SAP.0000000000000283.

6. Huang Wen-Chia, Lu I-Lin, Chiang Wen-Hsuan et al. Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma. J Control Release. 2017; 254: 119-130. doi: 10.1016/j.jconrel.2017.03.035.

7. Heraea Dumitru-Daniel, Labusca Luminita, Radu Ecaterina et al. Human adipose-derived stem cells loaded with drug-coated magnetic nanoparticles for in-vitro tumor cells targeting. Mater Sci Eng C Mater Biol Appl. 2019; 94: 666-676. doi: 10.1016/j.msec.2018.10.019.

8. Donnenberg Vera S, Zimmerlin Ludovic, Rubin Joseph Peter et al. Regenerative therapy after cancer: what are the risks?. Tissue Eng Part B Rev. 2010; 16: 567-75. doi: 10.1089/ten.TEB.2010.03.035.

9. Lin Guiting, Yang Rong, Banie Lia et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate. 2010; 70: 1066-73. doi: 10.1002/pros.21140.

10. Kalluri Raghu, Zeisberg Michael. Fibroblasts in cancer. Nat. Rev. Cancer. 2006, 6: 392-401. doi: 10.1038/nrc1877.

11. Jotzu Constantin, Alt Eckhard, Welte Gabriel et al. Adipose tissue derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor derived factors. Cell Oncol (Dordr). 2011; 34: 55-67. doi: 10.1007/s13402-011-0012-1.
12. Koellensperger Eva, Gramley Felix, Preisner Fabian et al. Alterations of gene expression and protein synthesis in co-cultured adipose tissue-derived stem cells and squamous cell-carcinoma cells: consequences for clinical applications. Stem Cell Res Ther. 2014; 5: 65. doi: 10.1186/scrt454.

13. Rouhani Panta, Fletcher Christopher D M, Devesa Susan S et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008; 113: 616-27. doi: 10.1002/cncr.23571.

14. Christopher K. Bichakjian. Dermatofibrosarcoma protuberans: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2019; 2(1), MS-2-3.

15. Ratner D, Thomas C O, Johnson T M et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J. Am. Acad. Dermatol. 1997; 37: 600-13. doi: 10.1016/s0190-9622(97)70179-8.

16. Criscione Vincent D, Weinstock Martin A, Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J. Am. Acad. Dermatol. 2007; 56: 968-73. doi: 10.1016/j.jaad.2006.09.006.

17. Pennati Angela, Riggio Egidio, Marano Giuseppe et al. Autologous fat grafting after sarcoma surgery: Evaluation of oncological safety. J Plast Reconstr Aesthet Surg. 2018; 71: 1723-1729. doi: 10.1016/j.bjps.2018.07.028.

18. Liang Chun-Chi, Park Ann Y, Guan Jun-Lin, In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007; 2: 329-33. doi: 10.1038/nprot.2007.30.

19. Ponce M Lourdes. Tube formation: an in vitro matrigel angiogenesis assay. Methods Mol. Biol. 2009; 467: 183-8.

20. Peach M, Marsh N, Macphee DJ. Protein solubilization: attend to the choice of lysis buffer. Methods Mol Biol. 2012; 869:37-47. doi: 10.1007/978-1-61779-821-4_4.

21. Bourin Philippe, Bunnell Bruce A, Casteilla Louis et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013; 15: 641-8. doi: 10.1016/j.jcyt.2013.02.006.

22. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-379. doi: 10.1038/35077241.

23. Muehlberg Fabian L, Song Yao-Hua, Krohn Alexander et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis. 2009; 30: 589-97. doi: 10.1093/carcin/bgp036.
24. Dvorak H F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England journal of medicine. 1986; 315(26):1650. doi: 10.1056/NEJM198612253152606.

25. Kucerova Lucia, Altanerova Veronika, Matuskova Miroslava et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007; 67: 6304-13. doi: 10.1158/0008-5472.CAN-06-4024.

26. Hanahan Douglas, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74. doi: 10.1016/j.cell.2011.02.013.

27. Iser Isabele C, Ceschini Stefanie M, Onzi Giovana R et al. Conditioned Medium from Adipose-Derived Stem Cells (ADSCs) Promotes Epithelial-to-Mesenchymal-Like Transition (EMT-Like) in Glioma Cells In vitro. Mol. Neurobiol. 2016; 53: 7184-7199. doi: 10.1007/s12035-015-9585-4.

28. Preisner Fabian, Leimer Uwe, Sandmann Stefanie et al. Impact of Human Adipose Tissue-Derived Stem Cells on Malignant Melanoma Cells in An In Vitro Co-culture Model. Stem Cell Rev Rep. 2018; 14: 125-140. doi: 10.1007/s12015-017-9772-y.

29. Koellensperger Eva, Bonnert Lilly-Claire, Zoernig Inka et al. The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction. Stem Cell Res Ther. 2017; 8: 121. doi: 10.1186/s13287-017-0579-1.

30. Catalano Veronica, Turdo Alice, Di Franco Simone et al. Tumor and its microenvironment: a synergistic interplay. Semin. Cancer Biol. 2013; 23: 522-32. doi: 10.1016/j.semcancer.2013.08.007.

31. Jing Yingying, Han Zhipeng, Liu Yan et al. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS ONE. 2012; 7: e43272. doi: 10.1371/journal.pone.0043272.

32. Karnoub Antoine E, Dash Ajeeta B, Vo Annie P et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449: 557-63. doi: 10.1038/nature06188.

33. Smits A, Funa K, Vassbotn F S et al. Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am. J. Pathol. 1992; 140: 639-48.

34. Pedeutour F, Simon M P, Minoletti F et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res. 1995; 55: 2400-3.

35. Pedeutour F, Simon M P, Minoletti F et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenetic and Genome Research. 1996; 72(2-3):171-174.
36. Rutkowski Piotr, Van Glabbeke Martine, Rankin Cathryn J et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J. Clin. Oncol., 2010; 28: 1772-9. doi: 10.1200/JCO.2009.25.7899.

37. Shimizu A, O’Brien K P, Sjöblom T et al. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999; 59: 3719-23.

38. Blatti S P, Foster D N, Ranganathan G, et al. Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells. Proceedings of the National Academy of Sciences. 1988; 85(4):1119-1123.

39. Alvares O, Klebe R, Grant G, et al. Growth Factor Effects on the Expression of Collagenase and TIMP-1 in Periodontal Ligament Cells. Journal of Periodontology. 1995; 66(7):552-558.

40. Fabunmi R P, Baker A H, Murray E J et al. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochemical Journal. 1996, 315(1):335-342.

41. Folkman, Judah. Angiogenesis: an organizing principle for drug discovery?. Nature reviews drug discovery. 2007; 6(4):273-286. doi:10.1038/nrd2115.

42. Abramsson Alexandra, Lindblom Per, Betsholtz Christer. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 2003; 112: 1142-51. doi:10.1172/JCI18549.

43. Hellström M, Kalén M, Lindahl P et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999; 126: 3047-55.

44. O Potapova, H Fakhrai, D Mercola. Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. International Journal of Cancer. 2010; 66(5):669-677.

45. Ostman A , Heldin C H. Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Advances in Cancer Research, 2001, 80:1-38. doi: 10.1016/s0065-230x(01)80010-5.

46. Simon M P , Navarro M , Roux, Danièle et al. Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma Protuberans (DP). Oncogene. 2001; 20(23):2965-2975.doi: 10.1038/sj.onc.1204426.

47. Zhang Z, Wang Y, Zhang J et al. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Molecular Medicine Reports. 2018. doi: info:doi/10.3892/mmr.2018.8533.
48. Zhang Ying, Lin Lianjie, Jin Yu et al. Overexpression of WNT5B promotes COLO 205 cell migration and invasion through the JNK signaling pathway. Oncol Rep. 2016; 36: 23-30. doi: 10.3892/or.2016.4772.

49. Liu Jing, Shen Jia-Xin, Wu Hua-Tao et al. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med. 2018; 25: 211-223.

50. Nyberg Pia, Salo Tuula, Kalluri Raghu. Tumor microenvironment and angiogenesis. Front. Biosci. 2008; 13: 6537-53. doi:10.2741/3173.

51. Kim K J, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-844. doi:10.1038/362841a0.

52. Scavelli C, Vacca A, Di Pietro G et al. Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. Leukemia. 2004; 18(6):1054-1058. doi:10.1038/sj.leu.2403355.

53. Adams R H, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. NATURE REVIEWS MOLECULAR CELL BIOLOGY. 2007; 8(6):464-478. doi:10.1038/nrm2183.

54. Mercurio A M, Bachelder R E, Bates R C et al. Autocrine signaling in carcinoma: VEGF and the α6β4 integrin. seminars in cancer biology. 2004; 14(2):115-122. doi:10.1016/j.semcancer.2003.09.016.

55. M. J. Cross. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. trends in pharmacological sciences. 2001; 22(4):201-207. doi:10.1016/S0165-6147(00)01676-X.

56. Pepper M S, Ferrara N, Orci L et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochemical & Biophysical Research Communications. 1993; 189(2):824-831.

57. Gherardi E, Gray J, Stoker M et al. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proceedings of the National Academy of ences. 1989; 86(15):5844-5848.

1. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992; 119: 629-64.

59. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, Mildner M, Weninger W, Nakamura T, Tschachler E, Binder BR. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest. 1999; 79: 427-438. doi:10.1007/s001090050366.
60. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001; 158: 1111-1120. doi:10.1016/S0002-9440(10)64058-8.

61. Van Belle E, Wittenbachler B, Chen D, Silver M, Chang L, Schwall R, Isner JM. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998; 97: 381–390. doi:10.1161/01.CIR.97.4.381.

Figures

Figure 1
Characterization of human adipose-derived stem cells (ADSCs). The differentiation into (A) Alizarin Red-stained osteocytes (scale bar=100 μm), (B) Alcian blue-stained chondrocytes (scale bar=50 μm), and (C) oil red O-stained adipocytes (scale bar=50 μm) were induced. Flow cytometric analysis of ADSCs: ADSCs expressed (D) CD29+ (87.37%), (E) CD31+ (0.5%), (F) CD45+ (2.18%), (G) CD90+ (95.62%) marked with fluorescein isothiocyanate (FITC), (H) CD105+(96.32%), and (I) CD44+(98.98%) marked with phycoerythrin (PE).

(A) DMEM/F12 SF  (B) DMEM/F12 SF
Transwell→
DFSP cells ← ADSCs
Mono-cultured DFSP cells  Co-cultured DFSP cells

Figure 2
Model of DFSP cells co-cultured with ADSCs by Transwell. (A) DFSP cells cultured alone and (B) DFSP cells co-cultured with ADSCs in DMEM/F12 SF. ADSCs, adipose tissue-derived stem cells; DFSP, dermatofibrosarcoma protuberans; DMEM, Dulbecco's modified Eagle's medium; SF, serum free.
Effect of ADSC-CM on DFSP cells proliferation by CCK-8. CCK-8 assay was performed to measure proliferation rate in DFSP cells, which were treated with ADSC-CM or DMEM/F12 (control), at 1, 3, 5 and 7 days. **p<0.01 and ***p<0.001 indicate significant differences between two groups in three independent experiments. ADSCs, adipose tissue-derived stem cells; CCK-8, CCK-8, Cell Counting Kit-8; DFSP, dermatofibrosarcoma protuberans; DMEM, Dulbecco’s modified Eagle’s medium.
Figure 4

Effect of ADSC-CM on DFSP cell migration by scratch wound healing. The average initial wound width was measured and defined as 100%. (A) Inverted microscopic images of DFSP cells wound repair. DFSP cells were treated with ADSC-CM (experimental), DMEM/F12+10% FBS (positive controls), or DMEM/F12 SF (negative controls). Wound healing within the scrape line was recorded at 0, 6, 12, and 24 h. Yellow dashed lines indicate the margin of the scratch. Scale bars=75 μm. Semi-quantification of migration rate at (B) 6 h, (C) 12 h, and (D) 24 h post-wounding. The wound areas were quantified in five random low-power fields per well using an inverted microscope. *p<0.05 and **p<0.01 indicate significant differences between ADSC-CM and negative control groups in three independent experiments. ADSCs, adipose tissue-derived stem cells; CM, conditioned medium; DFSP, dermatofibrosarcoma protuberans; DMEM, Dulbecco's modified Eagle's medium; SF, serum free.
Figure 5

Effect of ADSCs on DFSP cell migration by Transwell assay. (A) The migratory DFSP cells were visualized by staining cells with crystal violet. Scale bars=50 μm. (B) Illustrations of Transwell co-culture systems in different conditions: DFSP cells were seeded onto the upper chambers with DMEM/F12+10% FBS (positive control), DMEM/F12 SF (negative control), or ADSCs (experimental) added to the lower chambers; then cell migration was determined at 12 and 24 h. The numbers of migrated cells at 12 h (C) and 24 h (D). Migrated cells were counted in five random low-power fields per chamber using an inverted microscope. *p<0.05 and ****p<0.0001 indicate significant differences between co-culture with ADSCs (experimental) and negative control groups in three independent experiments. ADSCs, adipose tissue-derived stem cells; DFSP, dermatofibrosarcoma protuberans; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; SF, serum free.
**Figure 6**

Effect of ADSC-CM on DFSP cells invasion by Transwell assay with pre-coated Matrigel. (A) The invasive DFSP cells were visualized by staining with crystal violet. Scale bars=50 μm. (B) Illustration of cell invasion assay using Transwell with pre-coated Matrigel in different conditions. DFSP cells were seeded onto the upper chambers with DMEM/F12+10%FBS (positive control), DMEM/F12 SF (negative control), or ADSC-CM (experimental), and DMEM/F12+5%FBS was added to the lower chambers. Cell invasion was then determined at 36 h. (C) The number of invasive cells at 36 h. Invasive cells were counted in five random low-power fields per chamber by using an inverted microscope. *p<0.05 indicates significant differences between experimental and negative control groups determined in three independent experiments. ADSCs, adipose tissue-derived stem cells; CM, conditioned medium; DFSP, dermatofibrosarcoma protuberans; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; SF, serum free.

![Image](image_url)

**Figure 7**

Induction of angiogenesis. (A) Representative images of HUVECs forming tubes upon treatment with different CMs. Scale bars = 500 μm. (B) Number of meshes, (C) total tube length, and (D) total branch length of HUVECs induced by ADSC-CM, DFSP-CM, and co-cultured DFSP/ADSC-CM at 4 h, respectively. **p<0.01 indicate significant differences between co-cultured DFSP/ADSC-CM and control groups (ADSC-CM or DFSP-CM) in at least three independent experiments. ADSCs, adipose tissue-derived stem cells;
Effect of ADSCs on DFSP-related gene and protein expression in DFSP cells. (A) Beta-type platelet-derived growth factor receptor (PDGFRB) and (B) collagen type I alpha 1 chain (COL1A1) gene expression levels in DFSP cells in a mono-culture (control group) or a co-culture with ADSCs (experimental group). Data were normalized to the level of control group. Each group was tested in triplicate. Results are shown as mean ± standard deviation. *p<0.05 and **p<0.01 indicate significant differences in relation to the control group. The protein levels of PDGFRB and COL1A1 (C-E) were measured by Western blotting in DFSP cells in the control and experimental groups. ADSCs, adipose tissue-derived stem cells; DFSP, dermatofibrosarcoma protuberans.
Figure 9

Effect of ADSCs on growth factor gene expression and protein secretion in DFSP cells and microenvironment. (A) Vascular endothelial growth factor (VEGF), (B) hepatocyte growth factor (HGF), and (C) basic fibroblast growth factor (bFGF) gene expression levels in DFSP cells in a mono-culture (control group) or co-culture with ADSCs (experimental group). Data are normalized to the level of the control group. Levels of (D) VEGF, (E) HGF, and (F) bFGF secretion levels in the supernatants of DFSP-mono-culture (control group) and DFSP-ADSC-co-culture (experimental group) at 48 h were detected by ELISA. *p<0.05, **p<0.01 and ***p<0.001 indicate significant differences in relation to the control group in three independent experiments. ADSCs, adipose tissue-derived stem cells; DFSP, dermatofibrosarcoma protuberans; ELISA, enzyme-linked immunosorbent assay.